Lacosamide Tablet, Film Coated
Product Images NDC 67877-733

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 67877-733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Laco-cart-200-2 (Laco Cart 200 2)

Lacosamide Tablets, USP 200 mg film-coated oral tablets packaging label from Ascend Laboratories, LLC. The label includes dosing unit information with 60 tablets per package, warnings, storage instructions, and manufacturer details indicating manufacturing by Alkem Laboratories, India. It features the NDC number 67877-736-31 and includes barcodes and regulatory symbols.*

FDA Label Image

Laco-cont-100-2 (Laco Cont 100 2)

Lacosamide Tablets USP 100 mg film-coated tablets label showing 90 count package. The label includes storage instructions, manufacturer Alkemi Laboratories Ltd., India, and distributor Ascend Laboratories, LLC, Parsippany, NJ. It also features the NDC 67877-734-90, a barcode, Rx only designation, and a caution for pharmacists regarding the Medication Guide.*

FDA Label Image

Laco-cont-150-2 (Laco Cont 150 2)

Lacosamide Tablets USP 150 mg film-coated tablet label showing storage instructions (20° to 25°C), packaging size of 500 tablets, and distribution by Ascend Laboratories LLC. It displays a barcode, NDC 67877-735-05, and a note to pharmacists about the medication guide. Manufactured by Alkem Laboratories Ltd., India.*

FDA Label Image

Laco-cont-50-2 (Laco Cont 50 2)

Lacosamide Tablets, USP 50 mg film-coated oral tablets label showing a package of 60 tablets. The label includes the NDC 67877-733-60, manufacturer Alkem Laboratories Ltd., India, and distributor Ascend Laboratories, LLC, Parsippany, NJ. Storage instructions and a barcode are also visible.*

FDA Label Image

Laco-fig1.jpg (Laco Fig1)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing seizure reduction percentages between placebo and various doses of Lacosamide across three studies. The vertical axis shows median seizure reduction percentages from 0% to 45%, and the horizontal axis categorizes placebo and Lacosamide doses (200 mg, 400 mg, 600 mg). Each study is presented separately, with Lacosamide doses generally showing higher median seizure reductions than placebo, some marked as statistically significant.*

FDA Label Image

Laco-fig2.jpg (Laco Fig2)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4' showing responder rates on the vertical axis (from -100% worsening to 100% improvement) versus percent of patients on the horizontal axis (100% to 0%). It compares placebo (N=359) with three doses of lacosamide: 200 mg/day (N=267), 400 mg/day (N=466), and 600 mg/day (N=202), illustrating differences in responder rates across patient percentages.*

FDA Label Image

Laco-str (Laco Str)

Chemical structure of lacosamide, the active ingredient in the product Lacosamide. The diagram shows the molecular arrangement including functional groups such as an amide, an ether, and a benzyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.